MX2017002374A - Composiciones y metodos para tratar trastornos de la vision. - Google Patents
Composiciones y metodos para tratar trastornos de la vision.Info
- Publication number
- MX2017002374A MX2017002374A MX2017002374A MX2017002374A MX2017002374A MX 2017002374 A MX2017002374 A MX 2017002374A MX 2017002374 A MX2017002374 A MX 2017002374A MX 2017002374 A MX2017002374 A MX 2017002374A MX 2017002374 A MX2017002374 A MX 2017002374A
- Authority
- MX
- Mexico
- Prior art keywords
- treat
- vision disorders
- compositions
- methods
- lanosterol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000029257 vision disease Diseases 0.000 title abstract 3
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 abstract 3
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 abstract 3
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 abstract 3
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 abstract 3
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 abstract 3
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 abstract 3
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 abstract 3
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 abstract 3
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 abstract 3
- 229940058690 lanosterol Drugs 0.000 abstract 3
- 201000004569 Blindness Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 229930182558 Sterol Natural products 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040721P | 2014-08-22 | 2014-08-22 | |
| US201562194120P | 2015-07-17 | 2015-07-17 | |
| PCT/US2015/046453 WO2016029199A1 (en) | 2014-08-22 | 2015-08-24 | Compositions and methods to treat vision disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017002374A true MX2017002374A (es) | 2017-09-15 |
Family
ID=55351326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002374A MX2017002374A (es) | 2014-08-22 | 2015-08-24 | Composiciones y metodos para tratar trastornos de la vision. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10471076B2 (https=) |
| EP (1) | EP3182977B1 (https=) |
| JP (1) | JP6706020B2 (https=) |
| KR (1) | KR20170048426A (https=) |
| CN (2) | CN111529481B (https=) |
| AU (1) | AU2015305199A1 (https=) |
| BR (1) | BR112017003529A2 (https=) |
| CA (1) | CA2958868A1 (https=) |
| EA (1) | EA035798B1 (https=) |
| HK (1) | HK1243325A1 (https=) |
| MX (1) | MX2017002374A (https=) |
| SG (1) | SG11201701377YA (https=) |
| WO (1) | WO2016029199A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170048426A (ko) | 2014-08-22 | 2017-05-08 | 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디. | 시각 장애를 치료하기 위한 조성물 및 방법 |
| JP2018522070A (ja) | 2015-07-27 | 2018-08-09 | キャタコア・インコーポレイテッドＣａｔａｃｏｒｅ， Ｉｎｃ． | 白内障の処置用組成物 |
| CN106074568B (zh) * | 2015-09-02 | 2021-05-14 | 盛世泰科生物医药技术(苏州)有限公司 | 一种用于预防和治疗白内障的眼用制剂及其制备方法 |
| CN107397745A (zh) * | 2016-08-24 | 2017-11-28 | 上海毕傲图生物科技有限公司 | 唑类化合物眼用制剂 |
| CN106344587A (zh) * | 2016-08-24 | 2017-01-25 | 上海毕傲图生物科技有限公司 | 羊毛甾醇类化合物眼用制剂 |
| KR102267924B1 (ko) * | 2017-01-25 | 2021-06-21 | 광저우 오쿠순 옵탈믹 바이오테크놀로지 캄파니 리미티드 | 라노스테롤 프로드러그 화합물 및 이의 제조 방법과 응용 |
| WO2019097434A1 (en) * | 2017-11-17 | 2019-05-23 | Mahmood Piraee | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders |
| CN109985052A (zh) * | 2017-12-29 | 2019-07-09 | 上海蓝木化工有限公司 | 三萜类化合物的新用途 |
| WO2019195761A2 (en) | 2018-04-05 | 2019-10-10 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| PL3828193T3 (pl) * | 2018-07-25 | 2025-06-23 | Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. | Postać krystaliczna związku proleku lanosterolu i jej zastosowanie |
| US12329763B2 (en) * | 2019-03-04 | 2025-06-17 | Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. | Composition of lanosterol prodrug compound, preparation method therefor and use thereof |
| MX2021009520A (es) | 2021-08-06 | 2023-02-07 | Foodvica S A De C V | Composicion oftalmica para el tratamiento de trastornos visuales. |
| CN115737654B (zh) | 2021-09-03 | 2025-11-21 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药预防和/或治疗白内障的眼用制剂 |
| CN116570706A (zh) * | 2022-02-09 | 2023-08-11 | 上海瑞吉康生物医药有限公司 | 使用多肽治疗白内障的方法 |
| WO2023198192A1 (zh) * | 2022-04-15 | 2023-10-19 | 广州润尔眼科生物科技有限公司 | 甾体化合物在制备预防和/或治疗老花眼的药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9216106B2 (en) * | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
| WO2005084208A2 (en) * | 2004-02-27 | 2005-09-15 | New York University | A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression |
| US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| US20100068251A1 (en) * | 2006-10-10 | 2010-03-18 | Jina Pharmaceuticals, Inc. | Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof |
| WO2009107753A1 (ja) * | 2008-02-29 | 2009-09-03 | 財団法人 名古屋産業科学研究所 | 後眼部到達用リポソーム及び後眼部疾患用医薬組成物 |
| RU2476226C2 (ru) * | 2008-08-05 | 2013-02-27 | Амазония Фитомедикаментос Лтда | Фармацевтические применения ланоста-8,24-диен-3-олов |
| KR20150036578A (ko) * | 2012-07-17 | 2015-04-07 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 백내장의 치료를 위한 알파-크리스탈린 응집의 억제제 |
| JP2015526515A (ja) * | 2012-08-31 | 2015-09-10 | ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ | オメガ３脂肪酸を有する眼用組成物 |
| KR20170048426A (ko) | 2014-08-22 | 2017-05-08 | 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디. | 시각 장애를 치료하기 위한 조성물 및 방법 |
-
2015
- 2015-08-24 KR KR1020177007882A patent/KR20170048426A/ko not_active Withdrawn
- 2015-08-24 MX MX2017002374A patent/MX2017002374A/es unknown
- 2015-08-24 AU AU2015305199A patent/AU2015305199A1/en not_active Abandoned
- 2015-08-24 EP EP15834065.3A patent/EP3182977B1/en active Active
- 2015-08-24 CA CA2958868A patent/CA2958868A1/en not_active Abandoned
- 2015-08-24 WO PCT/US2015/046453 patent/WO2016029199A1/en not_active Ceased
- 2015-08-24 CN CN202010136027.9A patent/CN111529481B/zh active Active
- 2015-08-24 JP JP2017529981A patent/JP6706020B2/ja active Active
- 2015-08-24 EA EA201790397A patent/EA035798B1/ru not_active IP Right Cessation
- 2015-08-24 CN CN201580057679.0A patent/CN107206009B/zh active Active
- 2015-08-24 SG SG11201701377YA patent/SG11201701377YA/en unknown
- 2015-08-24 BR BR112017003529A patent/BR112017003529A2/pt not_active Application Discontinuation
- 2015-08-24 HK HK18102775.7A patent/HK1243325A1/zh unknown
-
2016
- 2016-04-26 US US15/139,192 patent/US10471076B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017525769A (ja) | 2017-09-07 |
| US20170065617A1 (en) | 2017-03-09 |
| CA2958868A1 (en) | 2016-02-25 |
| AU2015305199A1 (en) | 2017-04-13 |
| EP3182977B1 (en) | 2021-05-05 |
| CN111529481A (zh) | 2020-08-14 |
| WO2016029199A1 (en) | 2016-02-25 |
| KR20170048426A (ko) | 2017-05-08 |
| EA201790397A1 (ru) | 2017-08-31 |
| EA035798B1 (ru) | 2020-08-12 |
| SG11201701377YA (en) | 2017-03-30 |
| CN107206009B (zh) | 2020-03-27 |
| EP3182977A4 (en) | 2018-04-11 |
| US10471076B2 (en) | 2019-11-12 |
| HK1243325A1 (zh) | 2018-07-13 |
| CN107206009A (zh) | 2017-09-26 |
| CN111529481B (zh) | 2023-09-15 |
| BR112017003529A2 (pt) | 2019-08-20 |
| JP6706020B2 (ja) | 2020-06-03 |
| EP3182977A1 (en) | 2017-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017002374A (es) | Composiciones y metodos para tratar trastornos de la vision. | |
| MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
| MX2022000754A (es) | Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal. | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| PH12018500586B1 (en) | Farnesoid x receptor agonists and uses thereof | |
| EP4610279A3 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| HK1258588A1 (zh) | 用於治疗眼科疾病的化合物和制剂 | |
| EP4335418A3 (en) | Compositions and methods for treating pterygium | |
| MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| PH12018502161A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| WO2018094106A3 (en) | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES | |
| MX2020009709A (es) | Composiciones farmaceuticas que comprenden acido dihomo-gamma-linolenico (dgla) y uso de las mismas. | |
| EA201790893A1 (ru) | Способы лечения офтальмологических расстройств | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| EP3634438A4 (en) | COMPOSITIONS FOR THE TREATMENT OF NETWORK DISEASES AND METHOD FOR THEIR MANUFACTURE AND USE | |
| IL280952A (en) | Methods and drug compounds for the treatment of ophthalmic diseases | |
| EA201800565A1 (ru) | Композиция для лечения заболеваний уха, содержащая (+)-азасетрон | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| MX2018003799A (es) | Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla. | |
| PH12017501694B1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations |